Atheroprotective CD40-TRAF6 inhibitors: translational pipeline towards a clinical application

Back

ESC Professional Premium Access

Atheroprotective CD40-TRAF6 inhibitors: translational pipeline towards a clinical application

Session: Therapeutic strategies to combat vascular disease

Topic: Drugs, Drug Targets

Speaker: Doctor V. Bazioti (Munich, DE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Venetia Bazioti

Ludwig-Maximilians University, Munich (Germany)

0 follower

7 more presentations in this session

Characterization of AT-02, a pan-amyloid-binding peptide fusion immunoglobulin with high binding potency, complement activation, and immune cell stimulation

Speaker: Professor J. Wall (Knoxville, US)

Dapagliflozin downregulates G protein-coupled receptor Kinase-2 and upregulates regulator of g protein signaling-4 in adrenals to exert sympatholysis in heart failure

Speaker: Associate Professor A. Lymperopoulos (Fort Lauderdale, US)

Effective cardiac mRNA delivery using lipid nanoparticles

Speaker: Ms M. Labonia (Utrecht, NL)

HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction

Speaker: Doctor J. Schoelermann (Montreal, CA)

Dapagliflozin decreases atherosclerotic plaque instability via regulating macrophage pyroptosis

Speaker: Doctor L. Xu (Shanghai, CN)

Access the full session

Therapeutic strategies to combat vascular disease

Speakers: Doctor V. Bazioti, Professor J. Wall, Associate Professor A. Lymperopoulos, Ms M. Labonia, Doctor J. Schoelermann...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Atheroprotective CD40-TRAF6 inhibitors: translational pipeline towards a clinical application

About the speaker

Doctor Venetia Bazioti

7 more presentations in this session

Characterization of AT-02, a pan-amyloid-binding peptide fusion immunoglobulin with high binding potency, complement activation, and immune cell stimulation

Dapagliflozin downregulates G protein-coupled receptor Kinase-2 and upregulates regulator of g protein signaling-4 in adrenals to exert sympatholysis in heart failure

Effective cardiac mRNA delivery using lipid nanoparticles

HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction

Dapagliflozin decreases atherosclerotic plaque instability via regulating macrophage pyroptosis

Access the full session

Therapeutic strategies to combat vascular disease

About the event

ESC Congress 2023

ESC 365 is supported by